Paul Tudor Jones's CORT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 7,068 shares of Corcept Therapeutics Incorporated (CORT) worth $245,966, representing 0.00% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CORT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 135,902 shares. Largest reduction occurred in Q2 2020, reducing 95,643 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +7,068 | New Buy | 7,068 | $34.80 |
| Q1 2025 | -53,169 | Sold Out | 0 | $0.00 |
| Q4 2024 | +53,169 | New Buy | 53,169 | $50.39 |
| Q4 2023 | -51,242 | Sold Out | 0 | $0.00 |
| Q3 2023 | +25 | Add 0.05% | 51,242 | $27.24 |
| Q2 2023 | +3,338 | Add 6.97% | 51,217 | $22.25 |
| Q1 2023 | +47,879 | New Buy | 47,879 | $0.02 |
| Q4 2022 | -34,457 | Sold Out | 0 | $0.00 |
| Q3 2022 | +34,457 | New Buy | 34,457 | $25.63 |
| Q3 2020 | -77,417 | Sold Out | 0 | $0.00 |
| Q2 2020 | -95,643 | Reduce 55.27% | 77,417 | $16.82 |
| Q1 2020 | +13,606 | Add 8.53% | 173,060 | $11.89 |
| Q4 2019 | -15,908 | Reduce 9.07% | 159,454 | $12.10 |
| Q3 2019 | -61,904 | Reduce 26.09% | 175,362 | $14.14 |
| Q2 2019 | +21,806 | Add 10.12% | 237,266 | $11.15 |
| Q1 2019 | +53,058 | Add 32.67% | 215,460 | $11.74 |
| Q4 2018 | +135,902 | Add 512.84% | 162,402 | $13.36 |
| Q3 2018 | +26,500 | New Buy | 26,500 | $14.04 |
| Q2 2018 | -10,364 | Sold Out | 0 | $0.00 |
| Q1 2018 | +10,364 | New Buy | 10,364 | $16.40 |
| Q4 2017 | -34,734 | Sold Out | 0 | $0.00 |
| Q3 2017 | +34,734 | New Buy | 34,734 | $19.29 |
| Q4 2016 | -23,564 | Sold Out | 0 | $0.00 |
| Q3 2016 | -4,885 | Reduce 17.17% | 23,564 | $6.49 |
| Q2 2016 | -350 | Reduce 1.22% | 28,449 | $5.45 |
| Q1 2016 | +1,700 | Add 6.27% | 28,799 | $4.69 |
| Q4 2015 | +5,820 | Add 27.35% | 27,099 | $4.98 |
| Q3 2015 | +21,279 | New Buy | 21,279 | $3.76 |
Paul Tudor Jones's Corcept Therapeutics Incorporated Investment FAQs
Paul Tudor Jones first purchased Corcept Therapeutics Incorporated (CORT) in Q3 2015, acquiring 21,279 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Corcept Therapeutics Incorporated (CORT) for 28 quarters since Q3 2015.
Paul Tudor Jones's largest addition to Corcept Therapeutics Incorporated (CORT) was in Q4 2018, adding 162,402 shares worth $2.17 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 7,068 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $245,966.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Corcept Therapeutics Incorporated (CORT) was 237,266 shares, as reported at the end of Q2 2019.